Israel Englander’s Terns Pharmaceuticals TERN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-3,011,558
| Closed | -$159M | – | 6396 |
|
|
2026
Q1 | $159M | Buy |
3,011,558
+2,024,252
| +205% | +$83.1M | 0.07% | 279 |
|
|
2025
Q4 | $39.9M | Buy |
987,306
+45,722
| +5% | +$1.06M | 0.02% | 964 |
|
|
2025
Q3 | $7.07M | Sell |
941,584
-55,242
| -6% | -$353K | ﹤0.01% | 2751 |
|
|
2025
Q2 | $3.72M | Sell |
996,826
-120,616
| -11% | -$377K | ﹤0.01% | 3284 |
|
|
2025
Q1 | $3.08M | Sell |
1,117,442
-492,773
| -31% | -$2.01M | ﹤0.01% | 3359 |
|
|
2024
Q4 | $8.92M | Buy |
1,610,215
+31,681
| +2% | +$215K | ﹤0.01% | 2293 |
|
|
2024
Q3 | $13.2M | Buy |
1,578,534
+438,142
| +38% | +$3.6M | 0.01% | 1946 |
|
|
2024
Q2 | $7.77M | Sell |
1,140,392
-2,292,400
| -67% | -$13.9M | ﹤0.01% | 2315 |
|
|
2024
Q1 | $22.5M | Buy |
3,432,792
+1,444,151
| +73% | +$9.43M | 0.01% | 1463 |
|
|
2023
Q4 | $12.9M | Buy |
1,988,641
+374,080
| +23% | +$1.98M | 0.01% | 1943 |
|
|
2023
Q3 | $8.12M | Sell |
1,614,561
-667,681
| -29% | -$4.24M | ﹤0.01% | 2246 |
|
|
2023
Q2 | $20M | Buy |
2,282,242
+1,199,859
| +111% | +$14M | 0.01% | 1388 |
|
|
2023
Q1 | $12.8M | Sell |
1,082,383
-374,822
| -26% | -$3.58M | 0.01% | 1727 |
|
|
2022
Q4 | $14.8M | Buy |
1,457,205
+1,074,492
| +281% | +$7.15M | 0.01% | 1717 |
|
|
2022
Q3 | $2.25M | Buy |
382,713
+105,025
| +38% | +$390K | ﹤0.01% | 3631 |
|
|
2022
Q2 | $689K | Buy |
277,688
+189,178
| +214% | +$378K | ﹤0.01% | 4706 |
|
|
2022
Q1 | $263K | Buy |
88,510
+35,229
| +66% | +$150K | ﹤0.01% | 5661 |
|
|
2021
Q4 | $377K | Buy |
+53,281
| New | +$444K | ﹤0.01% | 5300 |
|
|
2021
Q3 | – | Sell |
-14,769
| Closed | -$181K | – | 7248 |
|
|
2021
Q2 | $181K | Buy |
+14,769
| New | +$252K | ﹤0.01% | 6058 |
|
Other funds holding TERN
Israel Englander's TERN Position: Q2 2026 in Review
Israel Englander sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 3,011,558 shares — an estimated $159M sold.
Israel Englander first reported a position in TERN in Q2 2021 and held it in 19 quarters. The position peaked at $159M in Q1 2026. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.
- Israel Englander reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Israel Englander sold 3,011,558 Terns Pharmaceuticals shares in Q2 2026, an estimated $159M.
- Israel Englander first reported a position in Terns Pharmaceuticals in Q2 2021 and held it in 19 quarters.
- Israel Englander's Terns Pharmaceuticals position peaked at $159M in Q1 2026.
- 1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.
Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.